Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder

Last updated: May 6, 2024
Sponsor: The University of Texas Health Science Center, Houston
Overall Status: Active - Recruiting

Phase

1/2

Condition

Asperger's Disorder

Autism

Williams Syndrome

Treatment

Placebo

BB-12 with LGG (Higher Dose)

BB-12 with LGG (Lower Dose)

Clinical Study ID

NCT03514784
HSC-MS-17-0995
R01HD095158-02
  • Ages 4-16
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This protocol is a blinded randomized controlled study of the effects of BB-12 with LGG at different doses in 70 healthy children with autism spectrum disorders at lower and higher doses over an 56-day period and a 28- day observation period. The study is being conducted in order to assess safety and tolerability of the probiotic (BB-12 with LGG) at 2 different doses of BB-12 with LGG. Identifying effects on behaviors in healthy children with ASD using SRS-2 and ABC, GI symptoms using GI symptom severity index, and relevant biomarkers of inflammation, microbiota, and metabolites. Primary testing and procedures will be conducted at the University of Texas Health Science Center at Houston and Memorial Hermann.

Biomarker identification includes Integrative analysis of plasma metabolome and stool microbiota will be conducted with the collaboration of Dr. Ruth Ann Luna and Dr. Jim Versalovic at Alkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology & Microbiology of Baylor College of Medicine.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Healthy children with autism spectrum disorders (4 - 16 years old) andgastrointestinal symptoms, based on the GI Severity Index, with no other recognizedillness will be enrolled in this study. There will be no selection on the basis ofage, race, or gender. Although the investigators anticipate the majority of subjectswill be male and/or pre-pubertal, in females of childbearing potential, a pregnancytest (urine) will be performed on females participating (at each visit).

Exclusion

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Subjects taking immunosuppressive medications, including oral corticosteroids
  • A History of Positive result of HIV, Hepatitis B, and/or Hepatitis C test
  • Abnormal lab test results (Section 5.2)
  • Gastrointestinal diseases such as celiac disease, inflammatory bowel disease
  • Subjects with an allergy to antibiotics
  • Presence of fever or a pre-existing adverse event monitored in the study
  • Use of probiotics in the last 30 days
  • Acute diarrheal illness within the past 30 days
  • Recent (within 2 weeks) or current use of oral antibiotics /anti-fungals Current useof oral laxatives
  • Subjects with implanted prosthetic devices including prosthetic heart valves
  • The investigators will require that subject not take any other probiotic-containingproducts, including yogurt supplemented with probiotics during the study period.

Study Design

Total Participants: 70
Treatment Group(s): 3
Primary Treatment: Placebo
Phase: 1/2
Study Start date:
May 01, 2016
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • UTHealth

    Houston, Texas 77030
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.